How Analysts Feel About MEDICURE INCORPORATED (OTCMKTS:MCUJF) After Increase in Sellers?

February 15, 2018 - By Peter Erickson

The stock of MEDICURE INCORPORATED (OTCMKTS:MCUJF) registered an increase of 22.58% in short interest. MCUJF’s total short interest was 3,800 shares in February as published by FINRA. Its up 22.58% from 3,100 shares, reported previously. With 1,300 shares average volume, it will take short sellers 3 days to cover their MCUJF’s short positions.

It closed at $5.82 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medicure Inc., a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company has market cap of $90.86 million. The firm primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It has a 8.24 P/E ratio. It is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications.

More important recent Medicure Inc. (OTCMKTS:MCUJF) news were published by: Marketwatch.com which released: “Medicure Inc.” on May 18, 2017, also Businesswire.com published article titled: “Medicure Acquires License to Sell and Market PREXXARTAN”, Nasdaq.com published: “Is Medicure Inc. (MCUJF) a Great Stock for Value Investors?” on September 20, 2017. More interesting news about Medicure Inc. (OTCMKTS:MCUJF) was released by: Seekingalpha.com and their article: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” with publication date: February 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: